生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 01-09 16:00:00

6,181.166

+23.376

+0.38%

最高6,196.655	最低6,019.152	成交量2.52亿
今开6,158.375	昨收6,157.789	日振幅2.88%
总市值0.00	流通市值0.00	总股本0.00
成交额67.02亿	换手率--	流通股本0.00
市净率8.152627	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":6181.1655,"timestamp":1767946113258,"preClose":6157.789,"halted":0,"volume":252194288,"delay":0,"changeRate":0.003796,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":23.376465,"latestTime":"01-09 16:00:00","open":6158.3745,"high":6196.6553,"low":6019.1523,"amount":6701852615,"amplitude":0.028826,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1767922200000,1767931200000],[1767934800000,1767945600000]],"pbRate":8.152627,"peRate":-81.891187,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2602559242","title":"医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559242","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602559242?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:24","pubTimestamp":1768137841,"startTime":"0","endTime":"0","summary":"海内外共振，加速抢占全球科技高地：脑机接口技术当前已经成为全球各国科技竞争的战略高地之一。当前全球脑机接口真处于爆发前夜，我国脑机接口产业有望迎来黄金发展期，建议关注微创脑科学、翔宇医疗、美好医疗等。从自免角度，建议关注康诺亚、益方生物、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","09926","03933","02172","BK1100","BK1161","BK1574","BK1617","BK1515","09939","02228","01276"],"gpt_icon":0},{"id":"2602551665","title":"博安生物(06955)：成交量异常变动及地舒单抗(60MG)在玻利维亚获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551665","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602551665?lang=zh_cn&edition=full","pubTime":"2026-01-11 18:26","pubTimestamp":1768127189,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，本公司董事会注意到本公司股份(H股)于2026年1月9日的成交量有所上升。董事会欣然宣布，其自主研发的地舒单抗注射液已获玻利维亚国家药品和卫生技术局批准上市。2022年，BA6101(博优倍)作为首个国产地舒单抗注射液在中国率先获批上市。具体而言，BA6101在质量、安全性和有效性方面均证实与原研参照药高度相似，无临床意义上的差异。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2602551189","title":"超 12 亿美元合作落地，超百款三抗研发三大趋势凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551189","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602551189?lang=zh_cn&edition=full","pubTime":"2026-01-11 07:20","pubTimestamp":1768087250,"startTime":"0","endTime":"0","summary":"2025 年 11 月，CS2009 联合疗法用于晚期实体瘤的 II 期临床 IND 获 CDE 批准。2025 年 6 月，SIM0500 的 I 期临床试验已在西奈山伊坎医学院 Tisch 癌症研究所完成首例美国患者给药。加速临床转化，拓展联合疗法近年来，三抗管线数量以及三抗 IND 申报数量呈现上升趋势。出海授权频发且合作层级升级国产三抗成为跨国药企 BD 布局的核心标的，头部企业密集达成超 10 亿美元级授权合作，泽璟 ZG006、先声 SIM0500 等产品相继授权艾伯维等国际巨头，覆盖大中华区以外全球权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111072320a4b507e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111072320a4b507e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2602853674","title":"每周股票复盘：*ST生物（000504）拟收购慧泽医药51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2602853674","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602853674?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:17","pubTimestamp":1768076227,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，*ST生物报收于8.84元，较上周的8.95元下跌1.23%。本周关注点公司公告汇总：*ST生物拟以现金收购湖南慧泽生物医药科技有限公司51%股权，交易构成重大资产重组。该事项已获董事会审议通过，不涉及关联交易，无需提交股东大会审议。亏损达净利润10%且超1000万元时需披露原因及套期有效性评估。南华生物拟以现金方式收购湖南慧泽生物医药科技有限公司51%股权，交易完成后慧泽医药将成为公司控股子公司并纳入合并报表范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","09939","159938","BK1515","BK1574","BK0042","BK0282","000504","BK0086","BK1161"],"gpt_icon":0},{"id":"2602753679","title":"每周股票复盘：荣昌生物（688331）拟回购股份金额不低于2000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602753679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602753679?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:14","pubTimestamp":1768076051,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，荣昌生物报收于96.96元，较上周的77.79元上涨24.64%。本周，荣昌生物1月9日盘中最高价报98.0元。荣昌生物当前最新总市值546.57亿元，在生物制品板块市值排名2/51，在两市A股市值排名365/5182。本周关注点公司公告汇总：荣昌生物拟使用自有资金回购股份，金额不低于2000万元且不超过4000万元。截至2025年12月31日，公司尚未开始回购股份，后续将根据市场情况择机实施回购，并按规定履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK1574","LU2328871848.SGD","688331","LU1064131003.USD","LU2488822045.USD","BK1161","BK1583","BK0239","LU2148510915.USD","09995","LU1064130708.USD"],"gpt_icon":0},{"id":"2602553569","title":"每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602553569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602553569?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:40","pubTimestamp":1768070417,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，诺诚健华报收于22.57元，较上周的20.52元上涨9.99%。本周，诺诚健华1月9日盘中最高价报22.85元。本周关注点公司公告汇总：截至2025年12月31日，诺诚健华总股本未变，已发行股份无增减。公司公告汇总：2023年及2024年人民币股激励计划合计剩余可授出14,176,450股。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09969","BK1574","BK1161","688428"],"gpt_icon":0},{"id":"2602533190","title":"每周股票复盘：君实生物（688180）董事长增持A股10万股耗资383.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533190?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:53","pubTimestamp":1768067589,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，君实生物报收于39.2元，较上周的34.16元上涨14.75%。截至2026年1月10日，熊俊通过集中竞价方式累计增持A股100,000股，约占总股本0.01%，累计成交金额383.84万元。本次增持计划尚未实施完毕，熊俊将继续择机增持。君实生物H股公告显示，截至2025年12月31日，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股总数为260,295,700股，在香港联交所上市；A股总数为766,394,171股，在上海证券交易所科创板上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1515","BK1161","BK0239","399300","BK1583","688180","159982"],"gpt_icon":0},{"id":"2602533143","title":"每周股票复盘：百济神州（688235）授出693,186股普通股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602533143?lang=zh_cn&edition=full","pubTime":"2026-01-11 01:52","pubTimestamp":1768067531,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百济神州报收于312.99元，较上周的268.6元上涨16.53%。本周，百济神州1月9日盘中最高价报317.84元。百济神州有限公司截至2025年12月31日，法定注册资本为231,146.38美元，已发行普通股总数为1,425,622,549股，另在上海科创板上市人民币股份115,055,260股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","LU1770034418.SGD","LU0588546209.SGD","LU1303224171.USD","BK1588","BK1583","LU1251922891.USD","LU0307460666.USD","LU1969619763.USD","688235","BK1500","06160","LU1719994722.HKD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2602584391","title":"公募开年力推医药基金！创新药迎“赚美元”新周期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602584391","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602584391?lang=zh_cn&edition=full","pubTime":"2026-01-10 17:09","pubTimestamp":1768036154,"startTime":"0","endTime":"0","summary":"在创新药定价逻辑跨进“赚美元”阶段之际，各大公募2026开年火速投放医药新基金。随着中国创新药行业逐步迈入“赚美元”的全球化变现周期，公募基金迅速推出各类医药新品。开年不足一周，创新药赛道便迎来了新产品发行的接力潮。基金料创新药拥抱全球化定价创新药赛道正迈向“赚美元”阶段，这一根本性转变，成为众多基金经理看好其估值重构的核心引擎。届时，中国创新药首批海外三期临床结果将陆续读出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110170933a70a63ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110170933a70a63ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","02228","BK1161","BK1141","BK1574","BK1617"],"gpt_icon":0},{"id":"2602458720","title":"天风·医药 | 炎症性肠病——市场空间大，研发路径愈发清晰，中国创新药公司有望深度参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2602458720","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602458720?lang=zh_cn&edition=full","pubTime":"2026-01-10 17:00","pubTimestamp":1768035600,"startTime":"0","endTime":"0","summary":"IBD的患者人群庞大，且存在未满足的治疗需求，2024年药物销售规模约240亿美金。现有治疗药物中，乌帕替尼综合疗效最优，但存在安全性问题。中国创新药公司有望深度参与IBD大赛道。2024年IBD患者数量接近91万人，并预计2025年患者数将达150万，由少见病走向常见病。中国创新药公司有望深度参与IBD大赛道在前沿靶点上，中国药企在TL1A方向储备较多，有超20款药物在研，覆盖单抗与双抗等形态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649150073&idx=3&sn=33ddf17fa4338eb2ef1ebec896a293b3&chksm=825e9afb02658828265e79311851b2ded48fd57cb041b4d431b7d1514651f9ac3bc8e49526b2&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2602960582","title":"罗氏从5.7亿美元从宜联生物引进B7H3 ADC，加码SCLC布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2602960582","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602960582?lang=zh_cn&edition=full","pubTime":"2026-01-10 16:41","pubTimestamp":1768034502,"startTime":"0","endTime":"0","summary":"1月8日，罗氏宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan中国以外地区的全球独家权益。双方于2024年初首次合作，达成一项价值近10亿美元的协议，共同开发宜联生物的ADC药物YL211，该药物靶向c-Met，用于治疗实体瘤。据宜联生物称，初步数据显示，该药物在SCLC二线治疗中展现出令人鼓舞的客观缓解率和生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2097828714.EUR","LU2242644610.SGD","LU2097828557.USD","LU2097828805.USD","BK1161","LU2097828474.EUR","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","LU2328871848.SGD","HK0000165453.HKD","MRK","BK1583","LU0502904849.HKD","BK1589","01801"],"gpt_icon":0},{"id":"2602818945","title":"一图速览 | 当前为什么看好创新药？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602818945","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602818945?lang=zh_cn&edition=full","pubTime":"2026-01-10 11:28","pubTimestamp":1768015680,"startTime":"0","endTime":"0","summary":"相关研报：华泰 | 医药：看好创新药流动性修复叠加多重催化","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649840617&idx=3&sn=f34c64b257b171a43bcdf615bc43d4b9&chksm=893fdacb440c67cf65fb0d03148258317031c229d87eaca19f741a231492cee96307980b7089&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2602585844","title":"小核酸药物行业跟踪点评：技术迭代驱动 慢病市场打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2602585844","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602585844?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:00","pubTimestamp":1767974400,"startTime":"0","endTime":"0","summary":"这意味着小核酸药物的战场已从肝脏疾病全面扩展至代谢、肺部、肌肉萎缩等肝脏外领域。从“跟随”到“并跑”，中国小核酸药物行业BD 出海创历史新高：中国小核酸药物行业在2025 年迎来了质的飞跃。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110112653a4b29978&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110112653a4b29978&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","01801","01877","BK1583"],"gpt_icon":0},{"id":"2602371238","title":"康宁杰瑞制药-B(09966)：KN035一线治疗BTC的NDA已获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602371238","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602371238?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:15","pubTimestamp":1767968124,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，中国国家药品监督管理局已正式受理KN035(恩沃利单抗注射液)(商标名：恩维达®)联合吉西他滨和奥沙利铂方案，用于一线治疗不可切除或转移性胆道癌的新药上市申请。此次受理基于III期临床试验(KN035-CN-005)的临床研究结果，这是一项针对中国晚期一线BTC患者设计的随机、平行对照、多中心III期临床试验。试验旨在评估 KN035联合GEMOX方案对比单纯GEMOX方案的疗效与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","XBTmain","BTC","09966","BK1161","BTCmain"],"gpt_icon":0},{"id":"2602374424","title":"达仁堂：中新医药不再纳入合并报表范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2602374424","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602374424?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:12","pubTimestamp":1767967920,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月9日，达仁堂在互动平台回答投资者提问时表示，2025年半年度及三季度购买商品、接受劳务支出的现金同比大幅下降，主要是2024年末公司将所属全资子公司天津中新医药有限公司（简称“中新医药”）的全部股权作价，增资津药太平医药有限公司，增资完成后，为公司的联营公司，中新医药不再纳入合并报表范围。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-09/doc-inhftpvi5683562.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-09/doc-inhftpvi5683562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","09939","BK0060","BK0188","BK0239","600329","BK1515","BK0028","159938","BK0164","BK1574"],"gpt_icon":0},{"id":"2602716213","title":"思路迪医药股份(01244)：恩维达®一线胆道癌新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602716213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602716213?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:05","pubTimestamp":1767967506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份(01244)发布公告，国家药品监督管理局(NMPA)已正式受理公司商业化产品恩维达® (通用名：恩沃利单抗注射液，原研代号：KN035)联合吉西他滨和奥沙利铂(GEMOX)方案，用于一线治疗不可切除或转移性胆道癌 (BTC)的新药上市申请(NDA)。此次受理基于III期临床试验(KN035-CN-005)的临床研究结果，这是一项针对中国晚期一线胆道癌患者设计的随机、平行对照、多中心III期临床试验，旨在评估恩维达®(KN035)联合GEMOX方案对比单纯GEMOX方案的疗效与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"思路迪医药股份(01244)：恩维达®一线胆道癌新药上市申请获国家药监局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01244"],"gpt_icon":0},{"id":"2602754883","title":"海南海药最新公告：创新药派恩加滨片Ⅱa期临床试验研究结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754883","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602754883?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:50","pubTimestamp":1767963010,"startTime":"0","endTime":"0","summary":"海南海药(000566.SZ)公告称，公司全资子公司海口市制药厂有限公司与中国科学院上海药物研究所联合研究开发的创新药派恩加滨项目，于近日完成了Ⅱa期临床试验，初步研究结果显示达到主要及次要临床终点。派恩加滨属于化药1类，为新型抗癫痫药物，新一代KCNQ钾通道激动剂，目前全球尚无上市品种，本品可用于难治性癫痫的治疗。本次仅为派恩加滨完成中国Ⅱa期临床试验结果分析，后续尚需完成Ⅱb期及Ⅲ期临床试验，并经国家药监局批准后方可上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","06978","BK1161","BK0060","BK1574","BK0146","000566","159992","BK0188","BK0239"],"gpt_icon":0},{"id":"2602327115","title":"九源基因(02566)拟采纳2026年股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327115","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602327115?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:12","pubTimestamp":1767957169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，于2026年1月9日，董事会已决议建议采纳本公司股份奖励计划(2026年股份奖励计划)。2026年股份奖励计划旨在吸引及挽留对本集团长期增长及成功作出重大贡献的合资格参与者，并认可及奖励2026年股份奖励计划合资格参与者(合资格参与者)过往对本集团作出的贡献;鼓励合资格参与者为本公司作出进一步贡献，并致力于为本公司及其股东(股东)的整体利益而提升本公司及其股份的价值;加强本公司的长期薪酬激励策略;及使合资格参与者的利益与本公司及其股东的利益趋于一致，以推动本集团的长期表现(无论是财务、业务或营运方面)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2602327673","title":"信诺维科创板IPO已问询 已开发10款主要在研创新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327673","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602327673?lang=zh_cn&edition=full","pubTime":"2026-01-09 18:56","pubTimestamp":1767956161,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月9日，苏州信诺维医药科技股份有限公司申请上交所科创板上市审核状态变更为“已问询”，国泰海通证券为其保荐机构，拟募资29.40亿元。公司已形成“1+3+N”的创新药管线2梯队，并通过全球BD3授权或转让初步实现了以研养研。公司在研管线获得的监管促进资格数量在国内药企中名列前茅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","159982","06978","159992"],"gpt_icon":0},{"id":"1172708678","title":"亿胜生物科技获准产品注册与商业化许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1172708678","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172708678?lang=zh_cn&edition=full","pubTime":"2026-01-09 18:35","pubTimestamp":1767954935,"startTime":"0","endTime":"0","summary":"亿胜生物科技有限公司近日宣布，其旗下某已获批准的产品成功取得了注册与商业化运营的正式许可。这一进展标志着该产品已满足相关监管要求，可正式进入市场销售与应用阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01061"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}